Endocrinological late effects after chemotherapy for testicular cancer.

por Berger, C. C., Bokemeyer, C., Schuppert, F., Schmoll, H. J.
Publicado 1996

The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.

por Bokemeyer, C., Schmoll, H. J., Ludwig, E., Harstrick, A., Dunn, T., Casper, J.
Publicado 1994

Long-term effects on sexual function and fertility after treatment of testicular cancer

por Hartmann, J T, Albrecht, C, Schmoll, H-J, Kuczyk, M A, Kollmannsberger, C, Bokemeyer, C
Publicado 1999

MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial

por Gormly, KLM, Coscia, C, Wells, T, Tebbutt, N, Harvey, JA, Wilson, K, Schmoll, H-J, Price, T
Publicado 2015

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.

por Bokemeyer, C., Fels, L. M., Dunn, T., Voigt, W., Gaedeke, J., Schmoll, H. J., Stolte, H., Lentzen, H.
Publicado 1996

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

por Bokemeyer, C., Berger, C. C., Hartmann, J. T., Kollmannsberger, C., Schmoll, H. J., Kuczyk, M. A., Kanz, L.
Publicado 1998

Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial

por Arnold, D, Voigt, W, Kiewe, P, Behrmann, C, Lindemann, S, Reif, S, Wiesinger, H, Giurescu, M, Thiel, E, Schmoll, H-J
Publicado 2009

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

por Jürgensmeier, J M, Schmoll, H-J, Robertson, J D, Brooks, L, Taboada, M, Morgan, S R, Wilson, D, Hoff, P M
Publicado 2013

First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial

por Bokemeyer, C, Schleucher, N, Metzner, B, Thomas, M, Rick, O, Schmoll, H-J, Kollmannsberger, C, Boehlke, I, Kanz, L, Hartmann, J T
Publicado 2003

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial

por Chu, E, Haller, D, Cartwright, T, Twelves, C, Cassidy, J, Sun, W, Saif, M W, McKenna, E, Lee, S, Schmoll, H-J
Publicado 2014

Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials

por Bokemeyer, C, Kollmannsberger, C, Stenning, S, Hartmann, J T, Horwich, A, Clemm, C, Gerl, A, Meisner, C, Rückerl, C-P, Schmoll, H-J, Kanz, L, Oliver, T
Publicado 2004

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorec...

por Tabernero, J., Grothey, A., Arnold, D., de Gramont, A., Ducreux, M., O’Dwyer, P., Tahiri, A., Gilberg, F., Irahara, N., Schmoll, H.-J., Van Cutsem, E.
Publicado 2022

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorect...

por Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., Giessen-Jung, C., Stahler, A., Schmoll, H. J., Jung, A., Kirchner, T., Tannapfel, A., Reinacher-Schick, A.
Publicado 2016

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

por Bleiberg, H., Decoster, G., de Gramont, A., Rougier, P., Sobrero, A., Benson, A., Chibaudel, B., Douillard, J. Y., Eng, C., Fuchs, C., Fujii, M., Labianca, R., Larsen, A. K., Mitchell, E., Schmoll, H. J., Sprumont, D., Zalcberg, J.
Publicado 2017